Core Insights - Ivanhoe Mines has released an updated independent technical report for the Kamoa-Kakula Copper Complex, indicating a significant mineral resource and reserve estimate that supports a long-term mining operation [2][10][16]. Group 1: Mineral Resource and Reserve Estimates - The Indicated Mineral Resource estimate stands at 1.3 billion tonnes with a grade of 2.65%, containing approximately 34 million tonnes of copper, which supports long-term optionality [1][6]. - The updated Mineral Reserve estimate is 466 million tonnes at a grade of 2.82%, containing 13.1 million tonnes of copper, which supports a multi-decade mine life [4][21]. - The Inferred Mineral Resources consist of an additional 336 million tonnes grading 1.82%, containing approximately 6.1 million tonnes of copper [6][17]. Group 2: Production Guidance and Cash Costs - The production guidance for Kamoa-Kakula has been revised to 290,000 to 330,000 tonnes of copper anodes in 2026, and 380,000 to 420,000 tonnes in 2027, with a target to exceed 500,000 tonnes from 2028 onwards [7][35][36]. - The cash cost (C1) guidance has been updated to $2.60/lb. to $3.00/lb. for 2026, decreasing to $2.10/lb. to $2.50/lb. for 2027, with a target of approximately $2.00/lb. from 2028 [34][36][59]. Group 3: Mine Plan and Feasibility Study - An updated mine plan supports the ramp-up of production to over 500,000 tonnes of copper per annum from 2028 onwards, incorporating phased concentrator operations [3][10]. - A feasibility study is currently in progress to optimize the mine plan and enhance operational definitions over the first five years [5][32][33]. Group 4: Leadership Changes - Ivanhoe Mines has strengthened its executive leadership team with the appointment of Simon Bottoms as Executive Vice President, Technical Services, and the promotion of Mark Sumner to Executive Vice President, Corporate Finance [43][45][48].

Core Viewpoint - The company plans to redirect funds that would have been allocated for Beck's future wages and bonuses towards research and development (R&D) projects [1] Group 1 - The company is reallocating financial resources to enhance its R&D initiatives [1]

Core Insights - BioHarvest Sciences Inc. reported FY2025 revenues of $34.5 million, reflecting a 37% increase compared to the previous year, with gross margins expanding to 59% [1][7] - The company successfully raised $19.9 million in an oversubscribed institutional financing round in Q4 2025 [1][10] - As of December 31, 2025, the company had cash and cash equivalents of $23 million, significantly up from $2.4 million in the previous year [1][15] Financial Performance - For Q4 2025, revenues increased by 25% year-over-year to $9.1 million, with gross margins at 58%, up 100 basis points from the previous year [7][13] - The adjusted EBITDA loss for Q4 2025 was $536,000, an improvement from a loss of $1.8 million in Q4 2024 [10][15] - The total operating expenses for Q4 2025 were $6.3 million, down from $5.8 million in the same quarter last year, representing 70% of total revenue compared to 80% previously [14] Business Segments - The Direct-to-Consumer (D2C) Products Division, particularly the VINIA brand, has become the No.1 resveratrol polyphenol brand in the U.S. market, with over 85,000 active users and $84 million in cumulative revenue since launch [1][8][17] - The CDMO (Contract Development and Manufacturing Organization) segment is expected to generate revenues of $4 million to $6 million in 2026, with significant investments planned for growth [3][4] - The company anticipates total consolidated revenue for 2026 to be in the range of $42 million to $48 million, with an estimated adjusted EBITDA loss of $3 million to $4 million [4][5] Strategic Initiatives - The company has launched new products, including VINIA Blood Flow Hydration, which has seen strong initial uptake and is expected to drive further marketing investments in 2026 [8][10] - BioHarvest has secured significant contract partnerships in the CDMO space, validating its Botanical Synthesis platform and expanding its operational capabilities [9][11] - The organization is focused on optimizing the performance of its two growth engines: the D2C product business and the CDMO services platform [5][9]

Industry Overview - The debate around artificial intelligence infrastructure has shifted to concerns about the physical capacity to meet investment needs in a timely manner as of March 26, 2026 [1] - Major companies like Amazon, Microsoft, Alphabet, and Meta are projected to invest over $630 billion in data centers and AI chips in 2026, with total capital outlay for the top 11 cloud and infrastructure companies potentially reaching $811 billion [2] - Data center and manufacturing projects accounted for 94% of the increase in non-residential construction spending in the U.S. from December 2023 to December 2024, indicating a significant economic driver in AI and high-performance computing [4] Company Insights Advanced Micro Devices, Inc. (NASDAQ:AMD) - As of March 30, 2026, 80% of analysts are positive on AMD, with a consensus price target of $300, suggesting a 48.52% upside [10] - Concerns regarding AMD's demand narrative were highlighted after Cathie Wood's sale of shares, which led to a 7.5% decline in stock price [11] - Analysts have mixed views, with Bernstein advising caution and a "Hold" rating, while RBC Capital maintains a "Sector Perform" rating, citing expected volume increases from OpenAI and Meta [12][13] Micron Technology, Inc. (NASDAQ:MU) - As of March 30, 2026, 94% of analysts maintain bullish ratings on Micron, with a consensus price target of $550, indicating a 53.97% upside [15] - Micron reported a record fiscal second-quarter with revenue increasing to $23.86 billion from $8.05 billion year-over-year, driven by AI-related demand [16] - The company is positioned as a key player in AI infrastructure, with a significant portion of DRAM consumption attributed to AI demand [17]

Core Insights - Co-Diagnostics reported a significant decline in revenue for the full year 2025, with total revenue of $0.6 million compared to $3.9 million in 2024, primarily due to lower grant revenue [2] - The company experienced an operating loss of $50.2 million in 2025, up from a loss of $40.1 million in 2024, largely driven by an $18.9 million non-cash impairment charge related to intangible assets [2][3] - The net loss for 2025 was $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share in 2024, reflecting the impact of impairment charges and reduced grant revenue [2][3] Financial Performance - Revenue for 2025 was $0.6 million, a decrease of 84% from $3.9 million in 2024 [2] - Operating expenses rose to $50.6 million in 2025 from $43.0 million in 2024, influenced by the impairment charge [2] - Adjusted EBITDA loss improved to $28.0 million in 2025 from a loss of $33.5 million in 2024 [2] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable investment securities totaled $11.9 million, down from $29.7 million at the end of 2024 [2] - The company closed two offerings, raising $3.8 million and $7.0 million through the sale of common stock [2] Strategic Developments - Co-Diagnostics is advancing its joint ventures, including CoSara Diagnostics in India and CoMira Diagnostics in Saudi Arabia, focusing on regulatory progress and manufacturing readiness [2][3] - The company is progressing with clinical evaluations for an upper respiratory multiplex test and expanding its AI capabilities within its diagnostic platform [2][3] - A new international patent was granted in Australia, enhancing the company's intellectual property portfolio [2] Future Outlook - The CEO emphasized the company's focus on executing its strategy centered on expanding its global footprint and advancing clinical programs toward regulatory milestones [3] - Plans for an initial FDA 510(k) submission for an upper respiratory test are underway, with the potential to incorporate COVID testing later if necessary [3]

Core Insights - MCAP Inc. reported a fourth quarter 2025 earnings per share (EPS) of $0.13, reflecting a 40% quarter-over-quarter increase, with quarterly EBITDA of $4.7 million and a full year EBITDA of $21 million [1]. Group 1: Financial Performance - The company achieved a quarterly EBITDA of $4.7 million for Q4 2025 [1]. - Full year EBITDA for 2025 was reported at $21 million [1]. - The EPS of $0.13 represents a significant increase of 40% compared to the previous quarter [1]. Group 2: Business Strategy - MCAP is focused on expanding its business through investments in customer relationships, application software development, and securities execution platforms [2]. - The company is actively seeking additional mergers and acquisitions (M&A) opportunities that align with its core competencies to enhance long-term shareholder value [2]. Group 3: Company Overview - MCAP Inc. is a U.S.-based public holding company with subsidiaries and investments in various companies, primarily in the financial technology sector [3]. - The company's main focus is on electronic market making, execution sector, securities trading technologies, and alternative trading platforms [3].

Core Insights - S&P Global, in collaboration with Cambridge Associates and Mercer, has launched the Private Markets Performance Analytics datasets aimed at providing standardized data for private credit and real assets, enhancing investors' ability to compare performance and manage risk [1][3]. Group 1: Dataset Features - The datasets are powered by S&P Global's iLEVEL portfolio monitoring platform and utilize a proprietary private markets taxonomy to standardize, aggregate, and anonymize data [2]. - The initial release includes comprehensive data across thousands of funds and their underlying assets, with future datasets for private equity and other asset classes expected later in 2026 [1][4]. Group 2: Investor Benefits - Investors can leverage these datasets to compare performance across similar investments using consistent metrics, manage risk through detailed market and deal-level data, and assess portfolio impacts from market events with increased speed and confidence [5]. - The datasets support various use cases, including portfolio performance monitoring, risk management, asset allocation decisions, fundraising analysis, and competitive insights, benefiting investment teams, risk managers, and senior leadership at both LP and GP organizations [4][5]. Group 3: Industry Context - The collaboration addresses the growing need for consistent, decision-ready intelligence in the evolving private markets landscape, transforming fragmented information into actionable insights for investors [3][4]. - As the number of managers in private markets increases, access to comprehensive performance data becomes crucial for making informed investment decisions [4].

Core Insights - Tvardi Therapeutics is advancing its clinical pipeline with two significant milestones expected in 2026: topline data from a healthy volunteer study of TTI-109 in Q2 and topline data from a Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H2 [1][3] Financial Performance - Research and development expenses for Q4 2025 were $5.5 million, down from $8.6 million in Q4 2024, while total R&D expenses for 2025 were $18.0 million compared to $23.7 million in 2024 [4] - General and administrative expenses for Q4 2025 were $2.1 million, slightly down from $2.2 million in Q4 2024, but increased for the full year to $8.7 million from $4.5 million in 2024 due to higher professional fees related to the merger with Cara Therapeutics [7] - The net loss for Q4 2025 was $7.3 million, an improvement from a net loss of $12.7 million in Q4 2024, with a full-year net loss of $18.2 million compared to $29.4 million in 2024 [8][9] Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.8 million, a slight decrease from $31.6 million in 2024, with the company expecting this cash runway to fund operations through Q4 2026 [10] Clinical Trials and Data - The ongoing healthy volunteer study of TTI-109 is expected to yield topline data in Q2 2026, while the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 will report topline results in the second half of 2026 [5][4] - Interim results from the REVERT IPF Phase 2 trial indicated a 9.4% reduction in fibrosis score for TTI-101 compared to 2.4% for placebo, alongside a 4.5-fold greater decline in IL-6 levels [4]

Core Insights - Jones Soda Co. reported a significant increase in revenue for Q4 2025, with a 450% rise to $11.7 million and a positive adjusted EBITDA of $0.5 million [1][3] - For the full year 2025, revenue increased by 42% to $25.3 million, with an adjusted EBITDA improvement of $5.2 million year-over-year [1][5] Financial Performance - Revenue from continuing operations rose by 42% to $25.3 million compared to $17.8 million in 2024, driven by new core soda sales and increased direct-to-consumer sales [3][5] - Adjusted gross profit margin from continuing operations increased to 32%, up from 27% in the previous year [3][6] - The net loss from continuing operations was reduced by 82% to $1.8 million, or $(0.01) per share, compared to a net loss of $9.9 million, or $(0.09) per share in 2024 [3][8] - Total operating expenses from continuing operations were $4.1 million, up from $3.2 million, primarily due to license and broker fees related to revenue growth [3][6] Business Highlights - The company launched new products, including Supply Pack and Rocket Bottle, in partnership with a leading gaming franchise [3][4] - Expanded distribution with a major warehouse club operator, significantly increasing product availability across Canada [3][4] - The company anticipates Q1 2026 revenue to exceed $12 million, representing a 260% increase year-over-year, and expects FY2026 revenue to exceed $40 million, up over 60% [2][11] Operational Improvements - The CEO highlighted that 2025 was a transformational year, marked by strong growth, expanded distribution, and operational improvements [4] - The company focused on streamlining operations, optimizing the supply chain, and implementing cost management strategies [4] Cash Position - As of December 31, 2025, the company had cash and cash equivalents of $3.6 million, up from $1.3 million at the end of 2024 [9]

Core Insights - Tvardi Therapeutics is advancing its clinical pipeline with two significant milestones expected in 2026: topline data from a healthy volunteer study of TTI-109 in Q2 and topline data from a Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H2 [1][3] Financial Performance - Research and development expenses for Q4 2025 were $5.5 million, down from $8.6 million in Q4 2024, while total R&D expenses for the full year 2025 were $18.0 million compared to $23.7 million in 2024, primarily due to reduced clinical costs for TTI-101 [4] - General and administrative expenses for Q4 2025 were $2.1 million, slightly down from $2.2 million in Q4 2024, but increased for the full year to $8.7 million from $4.5 million in 2024, mainly due to higher professional fees related to the merger with Cara Therapeutics [7] - The net loss for Q4 2025 was $7.3 million, an improvement from a net loss of $12.7 million in Q4 2024, with a full-year net loss of $18.2 million compared to $29.4 million in 2024 [8][9] Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.8 million, slightly down from $31.6 million in 2024, with the company expecting this cash runway to fund operations through Q4 2026 [10] Clinical Development Updates - The ongoing Phase 2 REVERT LIVER CANCER trial is expected to report topline results in the second half of 2026, allowing for additional data maturation and insights [5][6] - Preliminary data from the Phase 2 IPF trial of TTI-101 showed a 9.4% reduction in fibrosis score compared to 2.4% for placebo, indicating promising efficacy [5]